Cargando…
SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care
The COVID-19 pandemic has led to many problems in cancer patients, which in part are due to insufficient knowledge of the exact implications of the virus on these individuals. Perceptions based on known facts about previous pandemics and coronaviruses might not agree with actual real-life experience...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Southern Society for Clinical Investigation. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119956/ https://www.ncbi.nlm.nih.gov/pubmed/35605680 http://dx.doi.org/10.1016/j.amjms.2022.05.017 |
_version_ | 1784710798100135936 |
---|---|
author | Alaeddini, Mojgan Etemad-Moghadam, Shahroo |
author_facet | Alaeddini, Mojgan Etemad-Moghadam, Shahroo |
author_sort | Alaeddini, Mojgan |
collection | PubMed |
description | The COVID-19 pandemic has led to many problems in cancer patients, which in part are due to insufficient knowledge of the exact implications of the virus on these individuals. Perceptions based on known facts about previous pandemics and coronaviruses might not agree with actual real-life experience and objective findings. We present a compilation of scientific facts and actual observations on different aspects of SARS-CoV-2 infection in cancer patients. These patients are at increased risk of viral contraction and have higher chances of severe disease/mortality. The latter is impacted by other factors and is still debated. In contrast to preliminary impressions, the benefits of anti-cancer treatments outweigh their risks and should be continued. Cancer patients generate antibodies in response to vaccination but in lower amounts than healthy people, especially those with hematologic cancers. Boosters, including third doses, have shown increased immune-responses in most patients. Vaccination should be prioritized in these individuals. |
format | Online Article Text |
id | pubmed-9119956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Southern Society for Clinical Investigation. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91199562022-05-20 SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care Alaeddini, Mojgan Etemad-Moghadam, Shahroo Am J Med Sci Review Article The COVID-19 pandemic has led to many problems in cancer patients, which in part are due to insufficient knowledge of the exact implications of the virus on these individuals. Perceptions based on known facts about previous pandemics and coronaviruses might not agree with actual real-life experience and objective findings. We present a compilation of scientific facts and actual observations on different aspects of SARS-CoV-2 infection in cancer patients. These patients are at increased risk of viral contraction and have higher chances of severe disease/mortality. The latter is impacted by other factors and is still debated. In contrast to preliminary impressions, the benefits of anti-cancer treatments outweigh their risks and should be continued. Cancer patients generate antibodies in response to vaccination but in lower amounts than healthy people, especially those with hematologic cancers. Boosters, including third doses, have shown increased immune-responses in most patients. Vaccination should be prioritized in these individuals. Southern Society for Clinical Investigation. Published by Elsevier Inc. 2022-11 2022-05-20 /pmc/articles/PMC9119956/ /pubmed/35605680 http://dx.doi.org/10.1016/j.amjms.2022.05.017 Text en © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Alaeddini, Mojgan Etemad-Moghadam, Shahroo SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title | SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title_full | SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title_fullStr | SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title_full_unstemmed | SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title_short | SARS-Cov-2 infection in cancer patients, susceptibility, outcome and care |
title_sort | sars-cov-2 infection in cancer patients, susceptibility, outcome and care |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119956/ https://www.ncbi.nlm.nih.gov/pubmed/35605680 http://dx.doi.org/10.1016/j.amjms.2022.05.017 |
work_keys_str_mv | AT alaeddinimojgan sarscov2infectionincancerpatientssusceptibilityoutcomeandcare AT etemadmoghadamshahroo sarscov2infectionincancerpatientssusceptibilityoutcomeandcare |